Compare Stocks → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AEMDOTCMKTS:ARTHNASDAQ:AVGRNASDAQ:MOTS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$1.50-2.0%$1.65$1.35▼$5.00$3.94M1.888,436 shs442 shsARTHArch Therapeutics$1.18+3.5%$1.87$0.39▼$18.00$5.60M3.523,850 shs618 shsAVGRAvinger$3.85+4.1%$3.44$2.50▼$18.00$6.12M1.2645,830 shs12,431 shsMOTSMotus GI$0.08$0.50$0.05▼$23.40$402K1.31.37 million shs79,947 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical+1.20%+6.99%-12.07%-20.30%-66.00%ARTHArch Therapeutics+3.51%+1.72%-44.86%-71.15%-63.13%AVGRAvinger+0.27%0.00%+30.28%+27.59%-56.22%MOTSMotus GI+10.00%+1.32%-83.26%-91.78%-99.37%A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEMDAethlon Medical1.3651 of 5 stars3.53.00.00.01.10.00.6ARTHArch TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAVGRAvinger2.6267 of 5 stars3.55.00.00.01.90.80.6MOTSMotus GI1.209 of 5 stars3.53.00.00.00.60.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical3.00Buy$10.00565.34% UpsideARTHArch TherapeuticsN/AN/AN/AN/AAVGRAvinger3.00Buy$5.0029.87% UpsideMOTSMotus GI3.00Buy$28.8835,993.75% UpsideCurrent Analyst RatingsLatest AVGR, MOTS, ARTH, and AEMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2024AVGRAvingerHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/4/2024AEMDAethlon MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $10.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon Medical$570K6.91N/AN/A$6.56 per share0.23ARTHArch Therapeutics$80K69.94N/AN/A($2.43) per share-0.49AVGRAvinger$7.65M0.80N/AN/A($4.53) per share-0.85MOTSMotus GI$319K1.26N/AN/A$1.74 per share0.05Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$12.03M-$4.99N/AN/AN/AN/A-106.28%-86.60%6/26/2024 (Estimated)ARTHArch Therapeutics-$6.98MN/A0.00∞N/A-6,809.45%N/A-386.74%5/20/2024 (Estimated)AVGRAvinger-$18.32M-$26.34N/AN/AN/A-239.41%N/A-106.16%5/8/2024 (Estimated)MOTSMotus GI-$12.87M-$28.55N/A∞N/A-4,033.54%N/A-110.70%5/8/2024 (Estimated)Latest AVGR, MOTS, ARTH, and AEMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024Q4 2023AVGRAvinger$0.64-$3.93-$4.57-$3.93$2.52 million$1.91 million3/18/2024Q4 2023MOTSMotus GIN/A-$4.13-$4.13-$3.78N/A$0.06 million2/20/2024Q1 2024ARTHArch TherapeuticsN/A-$0.57-$0.57-$0.57N/A$0.05 million2/14/2024Q3 2024AEMDAethlon Medical-$1.23-$1.37-$0.14-$1.37N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/AARTHArch TherapeuticsN/AN/AN/AN/AN/AAVGRAvingerN/AN/AN/AN/AN/AMOTSMotus GIN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A3.933.93ARTHArch TherapeuticsN/A0.160.04AVGRAvingerN/A0.630.36MOTSMotus GI0.461.761.69OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%ARTHArch Therapeutics6.91%AVGRAvinger18.30%MOTSMotus GI20.06%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical4.00%ARTHArch Therapeutics4.50%AVGRAvinger11.40%MOTSMotus GI1.57%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical152.62 million2.52 millionNo DataARTHArch Therapeutics84.74 million4.53 millionNot OptionableAVGRAvinger681.59 million1.41 millionNot OptionableMOTSMotus GI155.03 million4.95 millionNot OptionableAVGR, MOTS, ARTH, and AEMD HeadlinesSourceHeadlineMotus GI Holdings Incmorningstar.com - April 16 at 5:43 PMWhy Is Motus GI (MOTS) Stock Down 37% Today?msn.com - April 12 at 8:50 AMWhy Is Motus GI (MOTS) Stock Down 37% Today?investorplace.com - April 12 at 8:32 AMMotus GI Holdings files to sell 4.4M common shares for holdersmsn.com - March 23 at 3:58 PMMotus GI Holdings, Inc.: Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 19 at 7:57 AMMOTS Stock Earnings: Motus GI Hldgs Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 18 at 11:01 PMLe BPA de Motus GI Holdings a dépassé les attentes de 1,30$, le CA en dessous des prévisionsfr.investing.com - March 18 at 9:55 PMMotus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - March 18 at 4:05 PMMotus GI Holdings, Inc. (MOTS)finance.yahoo.com - February 29 at 12:41 PMEndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officerbusinesswire.com - February 29 at 7:57 AMMotus GI secures new patent for endoscopic proceduresinvesting.com - February 23 at 10:53 PMMotus GI Holdings Inc.wsj.com - February 23 at 10:53 PMMotus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceedsfinance.yahoo.com - February 22 at 8:41 AMMotus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceedsglobenewswire.com - February 22 at 8:00 AMWhy Is Colonoscopy-Focused Motus GI Stock Trading Higher Today?msn.com - February 21 at 6:01 PMCrude Oil Moves Higher; Exelon Earnings Top Estimatesmarkets.businessinsider.com - February 21 at 1:00 PMMotus GI obtient un nouveau brevet pour les procédures endoscopiquesfr.investing.com - February 21 at 1:00 PMMotus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tractfinance.yahoo.com - February 21 at 1:00 PMMotus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tractglobenewswire.com - February 21 at 8:52 AMMotus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholdersfinance.yahoo.com - February 16 at 9:03 PMMotus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholdersglobenewswire.com - February 16 at 4:15 PMMotus GI Holdings Inc (MOTS)investing.com - February 14 at 7:15 AMMotus GI Holdings Inc MOTSmorningstar.com - February 8 at 11:15 AMMotus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparationfinance.yahoo.com - January 30 at 2:11 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAethlon MedicalNASDAQ:AEMDAethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.Arch TherapeuticsOTCMKTS:ARTHArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.AvingerNASDAQ:AVGRAvinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.Motus GINASDAQ:MOTSMotus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.